The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children
Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu časopisecké články
PubMed
24811685
DOI
10.12659/aot.889933
PII: 889933
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická aplikace a dávkování MeSH
- busulfan aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- dítě MeSH
- dithiokarb aplikace a dávkování MeSH
- intravenózní infuze MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- monitorování léčiv metody MeSH
- myeloablativní agonisté aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- předškolní dítě MeSH
- příprava pacienta k transplantaci škodlivé účinky metody MeSH
- tělesná hmotnost MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- busulfan MeSH
- dithiokarb MeSH
- myeloablativní agonisté MeSH
BACKGROUND: Series of observations indicate PK/PD variability challenging the accuracy of the body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose of this communication is to describe the frequency of dose changes in initially body-weight-based fixed IV Bu dose and to emphasize the importance of TDM. MATERIAL AND METHODS: Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before the 5th dose, followed by samples immediately after the end of the 2-h infusion peak, 4 h, and 6 h from initiation of the infusion) was performed in 46 of 62 subjects. Busulfan concentrations were determined by high-performance liquid chromatography (HPLC). AUC was calculated according to the trapezoidal rule. RESULTS: We observed trough levels of 25-1244 µg/L, peak levels of 849-4586 µg/L, and AUC of 2225-12818 µg/L·h following body weight-based high-dose busulfan. The doses were changed in 54% of cases. AUC in 5 of 9 patients with VOD were within target, in 3 patients AUS was higher, and in 1 patient AUC was lower. One of the 2 patients with neurotoxicity had higher AUC. Engraftment was 100%, but relapse occurred in 25% of cases. CONCLUSIONS: Our results demonstrate that even with IV busulfan, intra-individual PK/PD variability is challenging. Although AUC does not necessarily correspond with outcomes (due to the role of other factors the fact that doses were changed in 54% of cases underlines the importance of TDM.
Citace poskytuje Crossref.org
Inhibition of autoimmune Chagas-like heart disease by bone marrow transplantation